| Autor: |
Iriondo J; Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Gómez A; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Zubicaray J; Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Garcia-Martinez J; Pediatric Onco-Hematology Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Health Research Institute at Hospital de La Princesa (IIS-Princesa), 28006 Madrid, Spain., Abad L; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Matesanz C; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Giménez R; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Galán A; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Sanz A; Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Sebastián E; Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., González de Pablo J; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., de la Cruz A; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain., Ramírez M; Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Pediatric Onco-Hematology Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Health Research Institute at Hospital de La Princesa (IIS-Princesa), 28006 Madrid, Spain., Sevilla J; Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.; Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain. |
| Abstrakt: |
Cytogenetic studies are essential in the diagnosis and follow up of patients with bone marrow failure syndromes (BMFSs), but obtaining good quality results is often challenging due to hypocellularity. Optical Genome Mapping (OGM), a novel technology capable of detecting most types chromosomal structural variants (SVs) at high resolution, is being increasingly used in many settings, including hematologic malignancies. Herein, we compared conventional cytogenetic techniques to OGM in 20 patients with diverse BMFSs. Twenty metaphases for the karyotype were only obtained in three subjects (15%), and no SVs were found in any of the samples. One patient with culture failure showed a gain in chromosome 1q by fluorescence in situ hybridization, which was confirmed by OGM. In contrast, OGM provided good quality results in all subjects, and SVs were detected in 14 of them (70%), mostly corresponding to cryptic submicroscopic alterations not observed by standard techniques. Therefore, OGM emerges as a powerful tool that provides complete and evaluable results in hypocellular BMFSs, reducing multiple tests into a single assay and overcoming some of the main limitations of conventional techniques. Furthermore, in addition to confirming the abnormalities detected by conventional techniques, OGM found new alterations beyond their detection limits. |
